This has led to extensive studies on the combination of various small-molecule drugs, including epidermal growth factor receptor inhibitors in esophageal squamous cell carcinoma, BRAF or MEK inhibitors in melanoma [26,27], ALK inhibitors in neuroblastoma [28], and immune checkpoint inhibitors [29]. This evidence concerns the gene MAP2K7 and esophageal squamous cell carcinoma.